Phase II Trial of First-line Doxycycline for Ocular Adnexal Marginal Zone Lymphoma Treatment
Status:
Active, not recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
Objective of this trial is to establish the efficacy of an upfront targeted therapy
consisting of Chlamydophila psittaci (Cp)-eradicating therapy with prolonged administration
of doxycycline followed by eradication monitoring and antibiotic re-treatment at infection
re-occurrence in patients with newly diagnosed ocular adnexae marginal zone lymphoma The
primary endpoint is the 2-year progression-free survival (PFS) of patients with newly
diagnosed stage-IE lymphoma treated with the experimental strategy.
Phase:
Phase 2
Details
Lead Sponsor:
International Extranodal Lymphoma Study Group (IELSG)